WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience MBF Stereo Investigator
QUICK SEARCH:   [advanced]


     
-


HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (282)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kawarabayashi, T.
Right arrow Articles by Younkin, S. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kawarabayashi, T.
Right arrow Articles by Younkin, S. G.

 Previous Article  |  Next Article 

The Journal of Neuroscience, January 15, 2001, 21(2):372-381

Age-Dependent Changes in Brain, CSF, and Plasma Amyloid beta  Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease

Takeshi Kawarabayashi1, 2, Linda H. Younkin1, Takaomi C. Saido3, Mikio Shoji2, Karen Hsiao Ashe4, and Steven G. Younkin1

1 Mayo Clinic Jacksonville, Jacksonville, Florida 32224, 2 Department of Neurology, Gunma University, Gunma, Japan 371-8511, 3 Proteolytic Neuroscience Laboratory, RIKEN Brain Science Institute, Saitama, Japan 351-0198, and 4 Departments of Neurology and Neuroscience, Center for Clinical and Molecular Neurobiology, University of Minnesota, Minneapolis, Minnesota 55455

The accumulation of amyloid beta  protein (Abeta ) in the Tg2576 mouse model of Alzheimer's disease (AD) was evaluated by ELISA, immunoblotting, and immunocytochemistry. Changes in Abeta begin at 6-7 months as SDS-insoluble forms of Abeta 42 and Abeta 40 that require formic acid for solubilization appear. From 6 to 10 months, these insoluble forms increase exponentially. As insoluble Abeta appears, SDS-soluble Abeta decreases slightly, suggesting that it may be converting to an insoluble form. Our data indicate that it is full-length unmodified Abeta that accumulates initially in Tg2576 brain. SDS-resistant Abeta oligomers and most Abeta species that are N-terminally truncated or modified develop only in older Tg2576 mice, in which they are present at levels far lower than in human AD brain. Between 6 and 10 months, when SDS-insoluble Abeta 42 and Abeta 40 are easily detected in every animal, histopathology is minimal because only isolated Abeta cores can be identified. By 12 months, diffuse plaques are evident. From 12 to 23 months, diffuse plaques, neuritic plaques with amyloid cores, and biochemically extracted Abeta 42 and Abeta 40 increase to levels like those observed in AD brains. Coincident with the marked deposition of Abeta in brain, there is a decrease in CSF Abeta and a substantial, highly significant decrease in plasma Abeta . If a similar decline occurs in human plasma, it is possible that measurement of plasma Abeta may be useful as a premorbid biomarker for AD.

Key words: Alzheimer's disease; neurodegeneration; Tg2576 transgenic animal model; amyloid beta  protein; cerebrospinal fluid; plasma

Copyright © 2001 Society for Neuroscience  0270-6474/01/212372-10$05.00/0


This article has been cited by other articles:


Home page
 Am. J. Pathol.Home page
J. B. Paulson, M. Ramsden, C. Forster, M. A. Sherman, E. McGowan, and K. H. Ashe
Amyloid Plaque and Neurofibrillary Tangle Pathology in a Regulatable Mouse Model of Alzheimer's Disease
Am. J. Pathol., September 1, 2008; 173(3): 762 - 772.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. Quinn and M. N. Sabbagh
Detecting Alzheimer disease before it happens: The key to prevention?
Neurology, July 8, 2008; 71(2): 78 - 79.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
J. R. Steinerman, M. Irizarry, N. Scarmeas, S. Raju, J. Brandt, M. Albert, D. Blacker, B. Hyman, and Y. Stern
Distinct Pools of {beta}-Amyloid in Alzheimer Disease-Affected Brain: A Clinicopathologic Study
Arch Neurol, July 1, 2008; 65(7): 906 - 912.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. Wang, L. Ho, W. Zhao, K. Ono, C. Rosensweig, L. Chen, N. Humala, D. B. Teplow, and G. M. Pasinetti
Grape-Derived Polyphenolics Prevent A{beta} Oligomerization and Attenuate Cognitive Deterioration in a Mouse Model of Alzheimer's Disease
J. Neurosci., June 18, 2008; 28(25): 6388 - 6392.
[Abstract] [Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
X. Sun, D. C. Steffens, R. Au, M. Folstein, P. Summergrad, J. Yee, I. Rosenberg, D. M. Mwamburi, and W. Q. Qiu
Amyloid-Associated Depression: A Prodromal Depression of Alzheimer Disease?
Arch Gen Psychiatry, May 1, 2008; 65(5): 542 - 550.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
L. A. Kotilinek, M. A. Westerman, Q. Wang, K. Panizzon, G. P. Lim, A. Simonyi, S. Lesne, A. Falinska, L. H. Younkin, S. G. Younkin, et al.
Cyclooxygenase-2 inhibition improves amyloid-{beta}-mediated suppression of memory and synaptic plasticity
Brain, March 1, 2008; 131(3): 651 - 664.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Sankaranarayanan, E. A. Price, G. Wu, M.-C. Crouthamel, X.-P. Shi, K. Tugusheva, K. X. Tyler, J. Kahana, J. Ellis, L. Jin, et al.
In Vivo {beta}-Secretase 1 Inhibition Leads to Brain A{beta} Lowering and Increased {alpha}-Secretase Processing of Amyloid Precursor Protein without Effect on Neuregulin-1
J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 957 - 969.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
N. Ertekin-Taner, L. H. Younkin, D. M. Yager, F. Parfitt, M. C. Baker, S. Asthana, M. L. Hutton, S. G. Younkin, and N. R. Graff-Radford
Plasma amyloid {beta} protein is elevated in late-onset Alzheimer disease families
Neurology, February 19, 2008; 70(8): 596 - 606.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
J. Sundelof, V. Giedraitis, M. C. Irizarry, J. Sundstrom, E. Ingelsson, E. Ronnemaa, J. Arnlov, M. D. Gunnarsson, B. T. Hyman, H. Basun, et al.
Plasma {beta} Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men: A Prospective, Population-Based Cohort Study
Arch Neurol, February 1, 2008; 65(2): 256 - 263.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Park, P. Zhou, R. Pitstick, C. Capone, J. Anrather, E. H. Norris, L. Younkin, S. Younkin, G. Carlson, B. S. McEwen, et al.
Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein
PNAS, January 29, 2008; 105(4): 1347 - 1352.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. P. Imbimbo, E. Del Giudice, D. Colavito, A. D'Arrigo, M. D. Carbonare, G. Villetti, F. Facchinetti, R. Volta, V. Pietrini, M. F. Baroc, et al.
1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic Acid (CHF5074), a Novel {gamma}-Secretase Modulator, Reduces Brain beta-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease without Causing Peripheral Toxicity
J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 822 - 830.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
I. Petrushina, A. Ghochikyan, M. Mktrichyan, G. Mamikonyan, N. Movsesyan, H. Davtyan, A. Patel, E. Head, D. H. Cribbs, and M. G. Agadjanyan
Alzheimer's Disease Peptide Epitope Vaccine Reduces Insoluble But Not Soluble/Oligomeric A{beta} Species in Amyloid Precursor Protein Transgenic Mice
J. Neurosci., November 14, 2007; 27(46): 12721 - 12731.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. Maeda, B. Ji, T. Irie, T. Tomiyama, M. Maruyama, T. Okauchi, M. Staufenbiel, N. Iwata, M. Ono, T. C. Saido, et al.
Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography
J. Neurosci., October 10, 2007; 27(41): 10957 - 10968.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
W.-P. Chang, D. Downs, X.-P. Huang, H. Da, K.-M. Fung, and J. Tang
Amyloid-beta reduction by memapsin 2 (beta-secretase) immunization
FASEB J, October 1, 2007; 21(12): 3184 - 3196.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
H. K. Shin, P. B. Jones, M. Garcia-Alloza, L. Borrelli, S. M. Greenberg, B. J. Bacskai, M. P. Frosch, B. T. Hyman, M. A. Moskowitz, and C. Ayata
Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy
Brain, September 1, 2007; 130(9): 2310 - 2319.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
K. Zou, H. Yamaguchi, H. Akatsu, T. Sakamoto, M. Ko, K. Mizoguchi, J.-S. Gong, W. Yu, T. Yamamoto, K. Kosaka, et al.
Angiotensin-Converting Enzyme Converts Amyloid {beta}-Protein 1 42 (A{beta}1 42) to A{beta}1 40, and Its Inhibition Enhances Brain A{beta} Deposition
J. Neurosci., August 8, 2007; 27(32): 8628 - 8635.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. Mamikonyan, M. Necula, M. Mkrtichyan, A. Ghochikyan, I. Petrushina, N. Movsesyan, E. Mina, A. Kiyatkin, C. G. Glabe, D. H. Cribbs, et al.
Anti-Abeta1 11 Antibody Binds to Different beta-Amyloid Species, Inhibits Fibril Formation, and Disaggregates Preformed Fibrils but Not the Most Toxic Oligomers
J. Biol. Chem., August 3, 2007; 282(31): 22376 - 22386.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. L. Jankowsky, L. H. Younkin, V. Gonzales, D. J. Fadale, H. H. Slunt, H. A. Lester, S. G. Younkin, and D. R. Borchelt
Rodent Abeta Modulates the Solubility and Distribution of Amyloid Deposits in Transgenic Mice
J. Biol. Chem., August 3, 2007; 282(31): 22707 - 22720.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
A. Mouri, Y. Noda, H. Hara, H. Mizoguchi, T. Tabira, and T. Nabeshima
Oral vaccination with a viral vector containing A{beta} cDNA attenuates age-related A{beta} accumulation and memory deficits without causing inflammation in a mouse Alzheimer model
FASEB J, July 1, 2007; 21(9): 2135 - 2148.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
K.-J. Tsai, Y.-C. Tsai, and C.-K. J. Shen
G-CSF rescues the memory impairment of animal models of Alzheimer's disease
J. Exp. Med., June 11, 2007; 204(6): 1273 - 1280.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Ma, S. Lesne, L. Kotilinek, J. V. Steidl-Nichols, M. Sherman, L. Younkin, S. Younkin, C. Forster, N. Sergeant, A. Delacourte, et al.
Involvement of -site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity
PNAS, May 8, 2007; 104(19): 8167 - 8172.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
N. R. Graff-Radford, J. E. Crook, J. Lucas, B. F. Boeve, D. S. Knopman, R. J. Ivnik, G. E. Smith, L. H. Younkin, R. C. Petersen, and S. G. Younkin
Association of Low Plasma Abeta42/Abeta40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease
Arch Neurol, March 1, 2007; 64(3): 354 - 362.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. D. Best, D. W. Smith, M. A. Reilly, R. O'Donnell, H. D. Lewis, S. Ellis, N. Wilkie, T. W. Rosahl, P. A. Laroque, C. Boussiquet-Leroux, et al.
The Novel {gamma} Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) Reduces Amyloid Plaque Deposition without Evidence of Notch-Related Pathology in the Tg2576 Mouse
J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 552 - 558.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. Kim, L. Onstead, S. Randle, R. Price, L. Smithson, C. Zwizinski, D. W. Dickson, T. Golde, and E. McGowan
A{beta}40 Inhibits Amyloid Deposition In Vivo
J. Neurosci., January 17, 2007; 27(3): 627 - 633.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
A. Mendoza-Naranjo, C. Gonzalez-Billault, and R. B. Maccioni
Abeta1-42 stimulates actin polymerization in hippocampal neurons through Rac1 and Cdc42 Rho GTPases
J. Cell Sci., January 15, 2007; 120(2): 279 - 288.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
Y. Levites, L. A. Smithson, R. W. Price, R. S. Dakin, B. Yuan, M. R. Sierks, J. Kim, E. McGowan, D. K. Reed, T. L. Rosenberry, et al.
Insights into the mechanisms of action of anti-A{beta} antibodies in Alzheimer's disease mouse models
FASEB J, December 1, 2006; 20(14): 2576 - 2578.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
K.-J. Yin, J. R. Cirrito, P. Yan, X. Hu, Q. Xiao, X. Pan, R. Bateman, H. Song, F.-F. Hsu, J. Turk, et al.
Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-beta Peptide Catabolism
J. Neurosci., October 25, 2006; 26(43): 10939 - 10948.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
I. El Ghazi, B. L. Martin, and I. M. Armitage
Metallothionein-3 is a component of a multiprotein complex in the mouse brain.
Experimental Biology and Medicine, October 1, 2006; 231(9): 1500 - 1506.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
V. Stenset, L. Johnsen, D. Kocot, A. Negaard, A. Skinningsrud, P. Gulbrandsen, A. Wallin, and T. Fladby
Associations between white matter lesions, cerebrovascular risk factors, and low CSF Abeta42.
Neurology, September 12, 2006; 67(5): 830 - 833.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. Dvir, J. E. Friedman, J. Y. Lee, J. Y. Koh, F. Younis, S. Raz, I. Shapiro, A. Hoffman, A. Dahan, G. Rosenberg, et al.
A Novel Phospholipid Derivative of Indomethacin, DP-155 [Mixture of 1-Steroyl and 1-Palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl Choline], Shows Superior Safety and Similar Efficacy in Reducing Brain Amyloid beta in an Alzheimer's Disease Model
J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1248 - 1256.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
E. R. Peskind, G. Li, J. Shofer, J. F. Quinn, J. A. Kaye, C. M. Clark, M. R. Farlow, C. DeCarli, M. A. Raskind, G. D. Schellenberg, et al.
Age and Apolipoprotein E*4 Allele Effects on Cerebrospinal Fluid beta-Amyloid 42 in Adults With Normal Cognition.
Arch Neurol, July 1, 2006; 63(7): 936 - 939.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. H. Chang, M. J. Savage, D. G. Flood, J. M. Thomas, R. B. Levy, V. Mahadomrongkul, T. Shirao, C. Aoki, and P. T. Huerta
AMPA receptor downscaling at the onset of Alzheimer's disease pathology in double knockin mice
PNAS, February 28, 2006; 103(9): 3410 - 3415.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
D. P. CARDINALI, A. M. FURIO, and M. P. REYES
Clinical Perspectives for the Use of Melatonin as a Chronobiotic and Cytoprotective Agent
Ann. N.Y. Acad. Sci., December 1, 2005; 1057(1): 327 - 336.
[Abstract] [Full Text] [PDF]

Home page
 AJGPHome page
N. Pomara, L. M. Willoughby, J. J. Sidtis, and P. D. Mehta
Selective Reductions in Plasma A{beta} 1-42 in Healthy Elderly Subjects During Longitudinal Follow-Up: A Preliminary Report
Am J Geriatr Psychiatry, October 1, 2005; 13(10): 914 - 917.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
T. A. Comery, R. L. Martone, S. Aschmies, K. P. Atchison, G. Diamantidis, X. Gong, H. Zhou, A. F. Kreft, M. N. Pangalos, J. Sonnenberg-Reines, et al.
Acute {gamma}-Secretase Inhibition Improves Contextual Fear Conditioning in the Tg2576 Mouse Model of Alzheimer's Disease
J. Neurosci., September 28, 2005; 25(39): 8898 - 8902.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
J. L. Jankowsky, T. Melnikova, D. J. Fadale, G. M. Xu, H. H. Slunt, V. Gonzales, L. H. Younkin, S. G. Younkin, D. R. Borchelt, and A. V. Savonenko
Environmental Enrichment Mitigates Cognitive Deficits in a Mouse Model of Alzheimer's Disease
J. Neurosci., May 25, 2005; 25(21): 5217 - 5224.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. D. Best, M. T. Jay, F. Otu, J. Ma, A. Nadin, S. Ellis, H. D. Lewis, C. Pattison, M. Reilly, T. Harrison, et al.
Quantitative Measurement of Changes in Amyloid-{beta}(40) in the Rat Brain and Cerebrospinal Fluid following Treatment with the {gamma}-Secretase Inhibitor LY-411575 [N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]
J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 902 - 908.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Yang, G. P. Lim, A. N. Begum, O. J. Ubeda, M. R. Simmons, S. S. Ambegaokar, P. P. Chen, R. Kayed, C. G. Glabe, S. A. Frautschy, et al.
Curcumin Inhibits Formation of Amyloid {beta} Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo
J. Biol. Chem., February 18, 2005; 280(7): 5892 - 5901.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
L. Park, J. Anrather, P. Zhou, K. Frys, R. Pitstick, S. Younkin, G. A. Carlson, and C. Iadecola
NADPH Oxidase-Derived Reactive Oxygen Species Mediate the Cerebrovascular Dysfunction Induced by the Amyloid {beta} Peptide
J. Neurosci., February 16, 2005; 25(7): 1769 - 1777.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
N. Ertekin-Taner, J. Ronald, L. Feuk, J. Prince, M. Tucker, L. Younkin, M. Hella, S. Jain, A. Hackett, L. Scanlin, et al.
Elevated amyloid {beta} protein (A{beta}42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene
Hum. Mol. Genet., February 1, 2005; 14(3): 447 - 460.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. M. Barten, V. L. Guss, J. A. Corsa, A. Loo, S. B. Hansel, M. Zheng, B. Munoz, K. Srinivasan, B. Wang, B. J. Robertson, et al.
Dynamics of {beta}-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of {beta}-Amyloid Precursor Protein Transgenic Mice Treated with a {gamma}-Secretase Inhibitor
J. Pharmacol. Exp. Ther., February 1, 2005; 312(2): 635 - 643.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
M. M. Racke, L. I. Boone, D. L. Hepburn, M. Parsadainian, M. T. Bryan, D. K. Ness, K. S. Piroozi, W. H. Jordan, D. D. Brown, W. P. Hoffman, et al.
Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid {beta}
J. Neurosci., January 19, 2005; 25(3): 629 - 636.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S. L. Lambourne, L. A. Sellers, T. G. Bush, S. K. Choudhury, P. C. Emson, Y.-H. Suh, and L. S. Wilkinson
Increased tau Phosphorylation on Mitogen-Activated Protein Kinase Consensus Sites and Cognitive Decline in Transgenic Models for Alzheimer's Disease and FTDP-17: Evidence for Distinct Molecular Processes Underlying tau Abnormalities
Mol. Cell. Biol., January 1, 2005; 25(1): 278 - 293.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. A. Lanz, G. J. Fici, and K. M. Merchant
Lack of Specific Amyloid-{beta}(1-42) Suppression by Nonsteroidal Anti-Inflammatory Drugs in Young, Plaque-Free Tg2576 Mice and in Guinea Pig Neuronal Cultures
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 399 - 406.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. J. Chiocco, L. S. Kulnane, L. Younkin, S. Younkin, G. Evin, and B. T. Lamb
Altered Amyloid-{beta} Metabolism and Deposition in Genomic-based {beta}-Secretase Transgenic Mice
J. Biol. Chem., December 10, 2004; 279(50): 52535 - 52542.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
L. Zhao, B. Teter, T. Morihara, G. P. Lim, S. S. Ambegaokar, O. J. Ubeda, S. A. Frautschy, and G. M. Cole
Insulin-Degrading Enzyme as a Downstream Target of Insulin Receptor Signaling Cascade: Implications for Alzheimer's Disease Intervention
J. Neurosci., December 8, 2004; 24(49): 11120 - 11126.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
D. C. FEWLASS, K. NOBOA, F. X. PI-SUNYER, J. M. JOHNSTON, S. D. YAN, and N. TEZAPSIDIS
Obesity-related leptin regulates Alzheimer's A{beta}
FASEB J, December 1, 2004; 18(15): 1870 - 1878.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. Sung, H. Yang, K. Uryu, E. B. Lee, L. Zhao, D. Shineman, J. Q. Trojanowski, V. M.-Y. Lee, and D. Pratico
Modulation of Nuclear Factor-{kappa}B Activity by Indomethacin Influences A{beta} Levels but Not A{beta} Precursor Protein Metabolism in a Model of Alzheimer's Disease
Am. J. Pathol., December 1, 2004; 165(6): 2197 - 2206.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J.-H. Lee, K.-F. Lau, M. S. Perkinton, C. L. Standen, B. Rogelj, A. Falinska, D. M. McLoughlin, and C. C. J. Miller
The Neuronal Adaptor Protein X11{beta} Reduces Amyloid {beta}-Protein Levels and Amyloid Plaque Formation in the Brains of Transgenic Mice
J. Biol. Chem., November 19, 2004; 279(47): 49099 - 49104.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. H. Gylys, J. A. Fein, F. Yang, D. J. Wiley, C. A. Miller, and G. M. Cole
Synaptic Changes in Alzheimer's Disease: Increased Amyloid-{beta} and Gliosis in Surviving Terminals Is Accompanied by Decreased PSD-95 Fluorescence
Am. J. Pathol., November 1, 2004; 165(5): 1809 - 1817.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
R. Deane, Z. Wu, and B. V. Zlokovic
RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid {beta}-Peptide Clearance Through Transport Across the Blood-Brain Barrier
Stroke, November 1, 2004; 35(11_suppl_1): 2628 - 2631.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. Assini, S. Cammarata, A. Vitali, M. Colucci, L. Giliberto, R. Borghi, M. L. Inglese, S. Volpe, S. Ratto, F. Dagna-Bricarelli, et al.
Plasma levels of amyloid {beta}-protein 42 are increased in women with mild cognitive impairment
Neurology, September 14, 2004; 63(5): 828 - 831.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. A. Moss, N. H. Varvel, M. R. Nichols, D. K. Reed, and T. L. Rosenberry
Nordihydroguaiaretic Acid Does Not Disaggregate {beta}-Amyloid(1-40) Protofibrils but Does Inhibit Growth Arising from Direct Protofibril Association
Mol. Pharmacol., September 1, 2004; 66(3): 592 - 600.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
P. H. Reddy, S. McWeeney, B. S. Park, M. Manczak, R. V. Gutala, D. Partovi, Y. Jung, V. Yau, R. Searles, M. Mori, et al.
Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease
Hum. Mol. Genet., June 15, 2004; 13(12): 1225 - 1240.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
E. A. Stern, B. J. Bacskai, G. A. Hickey, F. J. Attenello, J. A. Lombardo, and B. T. Hyman
Cortical Synaptic Integration In Vivo Is Disrupted by Amyloid-{beta} Plaques
J. Neurosci., May 12, 2004; 24(19): 4535 - 4540.
[Abstract] [Full Text] [PDF]